CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Percutaneous Coronary Intervention for Chronic Total Occlusion—The Michigan Experience: Insights From the BMC2 Registry 2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease The spectrum of chronic coronary syndromes: genetics, imaging, and management after PCI and CABG Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery Disease The Elusive Late Benefit of Biodegradable Polymer Drug-Eluting Stents Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education?

Review Article2017 Feb 7;69(5):556-569.

JOURNAL:J Am Coll Cardiol. Article Link

Mode of Death in Heart Failure With Preserved Ejection Fraction

Vaduganathan M, Patel RB, Butler J et al. Keywords: epidemiology; mortality; outcomes

ABSTRACT


Little is known about specific modes of death in patients with heart failure with preserved ejection fraction(HFpEF). Herein, the authors critically appraise the current state of data and offer potential future directions. They conducted a systematic review of 1,608 published HFpEF papers from January 1, 1985, to December 31, 2015, which yielded 8 randomized clinical trials and 24 epidemiological studies with mode-of-death data. Noncardiovascular modes of death represent an important competing risk in HFpEF. Although sudden death accounted for ∼25% to 30% of deaths in trials, its definition is nonspecific; it is unclear what proportion represents arrhythmic deaths. Moving forward, reporting and definitions of modes of death must be standardized and tailored to the HFpEF population. Broad-scale systematic autopsies and long-term rhythm monitoring may clarify the underlying pathology and mechanisms driving mortal events. There is an unmet need for a longitudinal multicenter, global registry of patients with HFpEF to map its natural history.